News and Events

The Cardiac Depressant Factor DPP3 is Predicting Organ Failure in Burn Patients

Diagnostics company SphingoTec GmbH and 4TEEN4 Pharmaceuticals GmbH announced today the publication of new data showing that high blood levels of Dipeptidyl Peptidase 3 (DPP3) are indicating upcoming multiple organ failure and mortality risk in burn patients.

READ MORE ↵


Biotech Startup 4TEEN4 Pharmaceuicals Closes EUR 7 Million Series A Financing

Diagnostics company SphingoTec GmbH and 4TEEN4 Pharmaceuticals GmbH announced today the publication of new data showing that high blood levels of Dipeptidyl Peptidase 3 (DPP3) are indicating upcoming multiple organ failure and mortality risk in burn patients.

READ MORE ↵


4TEEN4 Pharmaceuticals reports first results on Procizumab, a novel therapeutic anti-DPP3 antibody for treatment of acute myocardial depression.

4TEEN4 Pharmaceuticals GmbH today for the first time reported preclinical data on its lead product Procizumab, a therapeutic antibody targeting circulating Dipeptidyl Peptidase 3 (DPP3) for the treatment of patients with acute myocardial depression including acute heart failure and cardiogenic shock.

READ MORE ↵